At a glance
ClinicalIndex Comparison RecordN/ACompleted· 146 enrolled
Drug / intervention
Renal Denervationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN) - POST MARKET APPROVAL CLINICAL SURVEILLANCE STUDY
In Brief
A clinical study evaluating Renal Denervation for Hypertension. Completed, enrolled 146 participants across 26 sites in 8 countries.
Detailed Summary
The Study objective is to assess the performance of the Vessix V2 Renal Denervation System for the treatment of uncontrolled hypertension using an innovative percutaneous Radio Frequency (RF) balloon catheter renal denervation device.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesAustralia, Austria, Belgium, France, Germany, Netherlands, New Zealand, Switzerland
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedMar 2012
Primary CompletionNov 2013
Study CompletionJun 2015
TodayJul 2026
First PostedMar 1, 2012
Enrollment StartFeb 1, 2012
Primary CompletionNov 1, 2013
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.3 years ago
Interventions
Renal Denervationdevice
percutaneous renal denervation using the Vessix RF balloon catheter